FOLH1 and metastatic malignant neoplasm in the lymph nodes: 2019 exhibited disease progression with extensive PSMA-avid lymph node and bone metastases; concurrent 18F-FDG PET/CT revealed increased glycolytic activity of the lymph node metastases.